Boston, United States
Solid Biosciences, founded in 2013 and headquartered in Charlestown, MA, USA, is a trailblazer in the biotechnology sector, especially in precision genetic medicine. Their motto, #TogetherWeAreSolid, reflects their commitment to advancing gene therapy solutions for rare neuromuscular and cardiac diseases.
Solid's innovative portfolio, including candidates like SGT-003 for Duchenne muscular dystrophy and SGT-212 for Friedreich’s ataxia, positions it at the forefront of healthcare technology and impact. The company's dedication to enhancing gene therapy delivery is further emphasized by their focus on developing genetic regulators and enabling technologies.
Solid Biosciences recently attracted significant attention from investors by securing a $109.00M post-IPO equity investment on 08 January 2024. This funding round drew support from renowned investors such as RA Capital Management, Invus, and Bain Capital Life Sciences, underlining industry confidence in Solid's mission and technological pipeline.
